Oncosec Medical Inc (ONCS) 5.75 $ONCS OncoSec Medical

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 9:16 PM

Oncosec Medical Inc (ONCS) 5.75 $ONCS

OncoSec Medical Inc. (Nasdaq: ONCS) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Mon Jul 06, 9:00AM CDT
What:
ONCS: 5.75 (-0.06), NDAQ: 50.48 (+1.26)

OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
PR Newswire - Mon Jul 06, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Joann V. Lofgren to the newly created position of Vice President of Market Development, effective July 6, 2015. In this role, Ms. Lofgren will be responsible for evaluating, designing, and executing on the company's market and product development strategy for all therapeutic products.
ONCS: 5.75 (-0.06)

OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell
PR Newswire - Wed Jul 01, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(Nasdaq: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that CEO and President Punit Dhillon will ring The Nasdaq Opening Bell in celebration of the Company's listing to The Nasdaq Stock Market at 9:30 am ET on July 7, 2015 at The Nasdaq MarketSite in New York City.
ONCS: 5.75 (-0.06)

OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer
PR Newswire - Thu Jun 25, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Richard B. Slansky as the Company's Chief Financial Officer, effective July 6, 2015. Mr. Slansky is responsible for leading financial operations and activities for OncoSec as well as managing financial plans and budgets. Veronica Vallejo, the current Chief Financial Officer of OncoSec, resigned from her position effective June 24, 2015 to pursue other opportunities.
ONCS: 5.75 (-0.06)

Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 11:40AM CDT

ACHC: 80.58 (+1.02), SGNL: 1.98 (-0.01), PRGO: 180.86 (+0.85), ESPR: 90.01 (+1.32), RXDX: 15.42 (+0.25), BAX: 37.61 (+0.59), UNH: 122.15 (+2.81), ONCS: 5.75 (-0.06), CVRS: 3.59 (-0.18), EGRX: 85.26 (+4.84), CASI: 1.70 (+0.05), PCRX: 67.54 (+0.20), BLRX: 2.29 (+0.05)

OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of
Stock Doctor - Seeking Alpha - Wed Jun 24, 10:39AM CDT
My investment strategy is simple. Find small-cap undervalued biotech companies with promising drugs and significant short and long term upside. My last article published a couple weeks ago detailed Tokai Pharmaceuticals (NASDAQ: TKAI ) and why its...
MRK: 57.95 (+0.57), ONCS: 5.75 (-0.06), BMY: 69.27 (+1.38)

OncoSec Medical Issues Annual Letter To Shareholders
PR Newswire - Wed Jun 17, 3:50PM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today issued the following letter from Punit Dhillon, President and CEO of OncoSec, to the company's shareholders. The letter and supplemental proxy information are available by clicking here.
ONCS: 5.75 (-0.06)

OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial
PR Newswire - Tue Jun 16, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse(TM) IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). ImmunoPulse(TM) IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to promote an anti-tumor immune response.
ONCS: 5.75 (-0.06)

OncoSec Medical Set to Join Russell Microcap Index
PR Newswire - Mon Jun 15, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it is set to join the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26, according to a preliminary list of additions posted on June 12.
ONCS: 5.75 (-0.06)

OncoSec Medical incurs higher net loss of USD14.7m for nine months fiscal year end 2015
M2 - Wed Jun 10, 3:48AM CDT
Cancer immunotherapies company OncoSec Medical (NasdaqCM:ONCS) stated on Monday its net loss of USD14.7m (USD1.19 per share) for the nine months ended 30 April 2015.
ONCS: 5.75 (-0.06)

OncoSec Medical reports 9M15 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:25AM CDT

ONCS: 5.75 (-0.06)

OncoSec Medical reports Q1 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:06AM CDT

ONCS: 5.75 (-0.06)

OncoSec Medical Announces Nine Months Results for Fiscal Year End 2015
PR Newswire - Tue Jun 09, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.
ONCS: 5.75 (-0.06)

OncoSec Medical concludes USD13.6m in registered direct offering
M2 - Tue Jun 09, 4:40AM CDT
Biopharmaceutical company OncoSec Medical (NasdaqCM:ONCS) reported on Monday the completion of its registered direct offering of 2,469,091 shares of its common stock.
ONCS: 5.75 (-0.06)

OncoSec Medical Closes $13.6 Million Registered Direct Offering
PR Newswire - Mon Jun 08, 4:27PM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share on June 8, 2015.
ONCS: 5.75 (-0.06)

Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)

OncoSec Medical to Present at the BIO International Convention
PR Newswire - Thu Jun 04, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the BIO International Convention on Wednesday, June 17 in Philadelphia. The presentation is scheduled to begin at 11:15 AM ET in Theater 4 at the Pennsylvania Convention Center.
ONCS: 5.75 (-0.06)

OncoSec Medical anticipates USD13.6m from registered direct offering
M2 - Thu Jun 04, 3:12AM CDT
OncoSec Medical (NasdaqCM:ONCS), a biopharmaceutical company developing its investigational ImmunoPulseTM intratumoral cancer immunotherapy, announced on Wednesday that it has entered into definitive agreements to raise about USD13.6m of securities in a registered direct offering.
ONCS: 5.75 (-0.06)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 11:45AM CDT

JRJC: 4.74 (-0.01), GLMD: 10.04 (+0.18), ESI: 3.81 (+0.04), LPTH: 1.90 (-0.01), GEVO: 2.71 (+0.26), ARDX: 17.67 (+1.21), VLTC: 4.77 (+0.11), MIND: 4.14 (-0.03), VISN: 11.82 (+1.83), EMITF: 1.35 (+0.02), STDY: 4.97 (+0.21), CPXX: 2.13 (+0.01), PXLW: 5.53 (+0.20), NOR: 0.52 (-0.07), FWM: 3.29 (-0.03), HTGM: 11.64 (-0.14), ONCS: 5.75 (-0.06), CBAY: 2.68 (-0.01), BLFS: 2.00 (-0.03), HQCL: 14.33 (-0.01)

OncoSec Medical Announces $13.6 Million Registered Direct Offering
PR Newswire - Wed Jun 03, 8:42AM CDT
OncoSec Medical Inc. ("OncoSec"

(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share.
ONCS: 5.75 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...